\
&
Contact us
\
&
Contact us
Published on | 10 months ago
Programmes AI ContinentDigital Europe project DS4SSCC-DEP (Data Space for Smart and Sustainable Cities and Communities) has opened its third and last round of cascade funding calls.
The aim of these Calls for Pilots is to validate an EU-wide cross-sectorial data space in practice and to advance its development and implementation to support policy priorities of cities and communities within the European Union, including the green-digital transformation based on secure and sovereign data infrastructure.
The pilot call is specifically designed for local public administrations in the EU and Digital Europe Programme (DEP) Associated countries and partners working with them (e.g., companies, civil society organisations, academia). The consortia must be capable of executing a cross-sectorial and cross-border pilot activity, and co-finance at least 50% of the pilot activity.
All relevant information on the background, objectives and scope of this call, as well as the conditions of participation, the available budget and the application templates can be found on the dedicated website of this call.
Deadline to submit proposals is 28 February 2025.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
